SPARCL1 (SPARC-like 1)
A matricellular protein implicated in tumor suppression and synaptic plasticity
Gene Information Card
| Symbol | SPARCL1 |
|---|---|
| Full Name | SPARC-like 1 (hevin) |
| Gene Type | protein-coding |
| Chromosomal Location | 4q22.1 |
| NCBI Gene ID | 8404 ncbi.nlm.nih.gov/gene/8404 |
| Ensembl ID | ENSG00000152583 |
| UniProt ID | Q14515 |
| OMIM ID | 606041 |
| HGNC ID | 11221 |
| Aliases | Hevin, SC1, MAST9, PIG33, ECM2 |
Description
SPARCL1 encodes a matricellular protein belonging to the SPARC family. It is involved in cell-extracellular matrix interactions, synaptic plasticity, and has been implicated as a tumor suppressor in various cancers. The protein is highly expressed in the brain and is downregulated in many tumor types.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Colorectal cancer | Downregulation of SPARCL1 promotes tumor growth and metastasis; loss of expression correlates with poor prognosis. | PMID: 19029980; COSMIC |
| Lung cancer | Reduced SPARCL1 expression is associated with increased invasiveness and worse survival. | PMID: 21573172; COSMIC |
| Prostate cancer | SPARCL1 acts as a tumor suppressor; its loss is linked to disease progression. | PMID: 23359662; COSMIC |
| Alzheimer disease | SPARCL1 is involved in synaptic function; altered expression may contribute to synaptic loss. | PMID: 25664854; NCBI Gene |
| Glioblastoma | SPARCL1 expression is decreased and correlates with tumor grade and patient outcome. | PMID: 20068132; COSMIC |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Brain | 62.3 | High |
| Lung | 12.1 | Medium |
| Heart | 8.5 | Medium |
| Liver | 1.2 | Low |
| Kidney | 3.4 | Low |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| SH-SY5Y (neuroblastoma) | 45.2 | High expression |
| A549 (lung carcinoma) | 2.8 | Low expression |
| HCT116 (colorectal carcinoma) | 1.5 | Very low expression |
| MCF7 (breast carcinoma) | 0.9 | Very low expression |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.1015C>T (p.Arg339*) | Nonsense | <0.1% in COSMIC | Loss of function; predicted to cause nonsense-mediated decay |
| c.1246G>A (p.Gly416Arg) | Missense | <0.1% in COSMIC | Unknown significance; may affect protein folding |
| c.157_158insA (p.Thr53Asnfs*2) | Frameshift | <0.1% in COSMIC | Loss of function; truncating |
Mutation functional classification
Loss of Function (LOF)
Nonsense and frameshift mutations (e.g., p.Arg339*, p.Thr53Asnfs*2) are predicted to result in loss of function via nonsense-mediated decay or truncation.
Gain of Function (GOF)
No gain-of-function mutations have been reported for SPARCL1.
Dominant Negative (DN)
No dominant-negative mutations have been described for SPARCL1.
View complete mutation data：
Gene Ontology (GO)
Pathways
• ECM-receptor interaction (KEGG: hsa04512)
• Focal adhesion (KEGG: hsa04510)
• PI3K-Akt signaling pathway (KEGG: hsa04151)
Protein Summary
SPARCL1 (hevin) is a 664-amino-acid secreted matricellular protein with an N-terminal SPARC-like domain, a follistatin-like domain, and an extracellular calcium-binding domain. It modulates cell-matrix interactions, inhibits cell adhesion, and regulates synaptic plasticity by promoting the formation of excitatory synapses. In cancer, SPARCL1 is frequently silenced by promoter methylation, leading to loss of its tumor-suppressive effects.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| SPARCL1 Knockout HEK293 Cell Line | EDJ-KQ5522 | Human | 8404 | Details Get a Quote |
| SPARCL1 Knockout HeLa Cell Line | EDJ-KQ54901 | Human | 8404 | Details Get a Quote |
| SPARCL1 Knockout A-549 Cell Line | EDJ-KQ63389 | Human | 8404 | Details Get a Quote |
| SPARCL1 Knockout HCT 116 Cell Line | EDJ-KQ71857 | Human | 8404 | Details Get a Quote |
Displaying Records 1 To 4 Of 4 Records
